- With
its Form 10 registration statement filing now effective, ETST will begin
reporting annual, quarterly and periodic financial statements to the SEC,
as well as other obligations
- Biotech
company is focused on the cannabidiol (CBD), pharmaceutical and
nutraceutical sectors, as well as the development, through subsidiaries,
of medical devices and research
- ETST
develops innovative products with the goal of becoming a world leader in
the CBD space; three new CBD formulas are being developed under a
provisory patent
Earth Science Tech, Inc. (OTC: ETST) anticipates uplisting
to the OTCQB Venture Market after receiving a Form 10 registration statement
filing date. The biotech company will begin filing annual reports with the SEC
on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K.
Additional reporting obligations include shareholder actions, proxies and stock
ownership rules (http://ibn.fm/r8kiR).
In a news release, Nickolas S. Tabraue, president, chairman
and director of ETST, said, “With our Form 10 filing now effective, ETST is
progressing towards fulfilling its goals. Following this achievement, we
anticipate to up-list to the OTCQB tier in early September, due to our early
application submission with OTC Markets Group, Inc. We look forward to maximizing
the value of our company for our loyal shareholders as we unfold.”
ETST is a biotech company based in Doral, Florida, marketing
and developing CBD products for the pharmaceutical and nutraceutical fields.
The company manufactures, markets and distributes its own cannabinoid products,
including capsules and oils.
In Canada, it is testing three new CBD IP formulations. It
is also testing its Hygee MSN-2 medical device, for the detection of sexually
transmitted infections (STIs) in women, at Québec’s Clinique Santé
Amitié (http://ibn.fm/IF36Y).
The company is developing two new products in Brazil through
a joint venture with Bionatus Laboratrio Botnico of Brazil and
its Canadian division, Bionatus Botanical Laboratories. In the
U.S., ETST is conducting studies with the University of Central Oklahoma on the
impact of high grade full spectrum CBD on breast cancer and immune cells (http://ibn.fm/jrbdu).
ETST holds several wholly owned subsidiaries. Cannabis
Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures
and distributes in the recreational sector. Earth Science Foundation, Inc. is
becoming a non-profit and accepts grants and donations to conduct additional
studies. Earth Science Pharmaceutical develops medical diagnostic tools and
vaccines. The company also formed subsidiary Canno Inno Laboratories Inc., a
strategic Montreal, Canada-based company that provides ETST with access to
government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
